HCPCS Code Descriptor:
Injection, tebentafusp-tebn, 1 microgram
Route of Administration:
KIMMTRAK is an Oncology drug manufactured by Immunocore and administered via the Intravenous route of administration. The J Code: J9274 is aligned to the drug KIMMTRAK.
Kimmtrak is a type of monoclonal antibody and is used to treat certain types of cancer. Kimmtrak works by slowing down preventing the growth of cancer cells. Kimmtrak is administered via a 15-to-20-minute intravenous infusion. Kimmtrak is a branded drug manufactured by Immunocore Commercial. From July 2022 to September 2022, Kimmtrak was assigned to the temporary C Code: C9095. Beginning in October 2022, Kimmtrak received the J Code: J9274. Patient assistance programs for this medication can be found through Immunocore.
Access Pricing and More By Registering
HCPCS Added Date:
HCPCS Effective Date:
HCPCS Short Description:
Inj, tebentafusp-tebn, 1 mcg
Billing and Coding Guide: